Patents Assigned to BIOWORKS, INC.
  • BIOSYNTHESIS OF OXYGENATED HYDROCARBONS
    Publication number: 20250075243
    Abstract: Described herein are CB5 polypeptides for the biosynthesis of oxygenated hydrocarbons in modified host cells.
    Type: Application
    Filed: September 10, 2024
    Publication date: March 6, 2025
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: Elena Brevnova, Bernardo Moura Torres da Costa, Krupanandan Haranahalli, Gabriel Rodriguez, Michael Torrens-Spence, Justin Vento
  • Compositions and methods for controlling plant pests and improving plant health
    Patent number: 12239137
    Abstract: Compositions and methods for controlling plant pests and/or improving at least one agronomic trait of interest in a plant are provided. Such compositions and methods comprise a bacterial strain that can be used as an inoculant for plants. Therefore, methods for growing a plant susceptible to a plant pest and/or plant disease caused by a plant pest and methods for controlling plant pests and/or plant disease on a plant susceptible to the plant pest and/or plant disease are also provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: March 4, 2025
    Assignee: Ginkgo Bioworks, Inc.
    Inventor: Esther Gachango
  • Biosynthesis of mogrosides
    Patent number: 12234464
    Abstract: Provided herein are enzymes (e.g., cucurbitadienol synthases (CDS), UDP-glycosyltransferases (UGT), C11 hydroxylases, epoxide hydrolases (EPH), squalene epoxidases, and/or cytochrome P450 reductases), host cells expressing the enzymes, and methods of producing mogrol precursors, mogrol, and/or mogrosides using such host cells.
    Type: Grant
    Filed: November 9, 2019
    Date of Patent: February 25, 2025
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Jeffrey Ian Boucher, Nicholas Flores, Jaide Jensen, Dayal Saran, Jue Wang
  • ENGINEERED SESQUITERPENE SYNTHASES
    Publication number: 20250027070
    Abstract: Provided in this disclosure are engineered sesquiterpene synthases, host cells expressing engineered sesquiterpene synthases and methods for making alpha-guaiene.
    Type: Application
    Filed: November 18, 2022
    Publication date: January 23, 2025
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: Jeffrey Ian Boucher, Dylan Alexander Carlin, Cinzia Formighieri, Bryan Greenhagen, Jaide Jensen, Scott Marr
  • ENGINEERED PHENYLALANINE AMMONIA LYASE ENZYMES
    Publication number: 20240425841
    Abstract: Aspects of the disclosure relate to phenylalanine ammonia lyase (PAL) enzymes, including engineered PAL enzymes, and their use in catalyzing chemical reactions.
    Type: Application
    Filed: September 8, 2022
    Publication date: December 26, 2024
    Applicants: Ginkgo Bioworks, Inc., Synlogic Operating Company, Inc.
    Inventors: Dylan Alexander Carlin, Ariel Hecht, Vincent Isablella, Jonathan Lewis McMurry, Catherine Monahan, Nikos Reppas, Christan Ridley, Nathan W. Schmidt
  • BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
    Publication number: 20240384307
    Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.
    Type: Application
    Filed: September 29, 2022
    Publication date: November 21, 2024
    Applicant: Ginkgo Bioworks, Inc.
    Inventor: Brian Carvalho
  • Virus vectors for targeting ophthalmic tissues
    Patent number: 12116384
    Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: October 15, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry
  • Antibody-evading virus vectors
    Patent number: 12091435
    Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: September 17, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry, James Kennon Smith
  • Chimeric terpene synthases
    Patent number: 12077799
    Abstract: Described herein are chimeric terpene synthases, methods for making chimeric terpene synthases, and methods for making terpenes using the same.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 3, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Christian Ridley, Jue Wang, Scott Marr
  • Antibody-evading virus vectors
    Patent number: 12060390
    Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: August 13, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry, James Kennon Smith
  • BIOSYNTHESIS OF ISOPRENOIDS AND PRECURSORS THEREOF
    Publication number: 20240218403
    Abstract: Described in this application are proteins and host cells involved in methods of producing isoprenoid precursors and/or isoprenoids.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 4, 2024
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: Guillaume Beaudoin, Elena Brevnova, Alkiviadis Orfefs Chatzivasileiou, Alexandra Exner, Annapuma Kamineni, Matthew McMahon, Joshua Trueheart
  • BIOSYNTHESIS OF MOGROSIDES
    Publication number: 20240200114
    Abstract: Described in this application are proteins and host cells involved in methods of producing mogrol precursors, mogrol, and/or mogrosides.
    Type: Application
    Filed: April 1, 2022
    Publication date: June 20, 2024
    Applicant: GINKGO BIOWORKS, INC.
    Inventors: Guillaume Beaudoin, Alexandra Exner, Annapurna Kamineni, Matthew McMahon, Joshua Trueheart
  • ANTIBODIES FOR SARS-COV-2 AND USES THEREOF
    Publication number: 20240190946
    Abstract: The disclosure relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The disclosure also relates to anti-SARS-COV-2 antibodies that have been obtained from subjects who became immune to this coronavirus, and to methods of using these anti-SARS-COV-2 antibodies. Methods for neutralizing SARS-COV-2 are disclosed, as well treatments for SARS-COV-2 using the anti-SARS-COV-2 antibodies.
    Type: Application
    Filed: December 20, 2023
    Publication date: June 13, 2024
    Applicant: Augmenta Bioworks, Inc.
    Inventors: Christopher J. Emig, Rosanna Man Wah Chau, Payam Shahi, Kim-Xuan Nguyen, YuShuan Lai, Robin Emig, John Beaber, Steven Henry, Marco Antonio Mena
  • PRODUCTION OF VACCINIA CAPPING ENZYME
    Publication number: 20240182877
    Abstract: Aspects of the disclosure relate to production of vaccinia capping enzyme (VCE) in host cells. For example, host cells may comprise: a promoter; a ribosome binding site (RBS); a nucleic acid encoding a vaccinia capping enzyme (VCE) or VCE subunit; and a terminator.
    Type: Application
    Filed: March 29, 2022
    Publication date: June 6, 2024
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: Josef Bober, Jeffrey Ian Boucher, Justin Michael Gardin, Jason King, Scott Marr, Matthew McMahon, Krishnaben S. Patel, Abraham Waldman
  • Recombinant adeno-associated virus vectors
    Patent number: 11981914
    Abstract: AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein are described. Also described are methods of administering the virus vectors and virus capsids to a cell or to a subject in vivo.
    Type: Grant
    Filed: September 25, 2023
    Date of Patent: May 14, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry
  • METHODS AND SYSTEMS FOR TARGETING AUTOIMMUNE AND INFLAMMATORY PATHWAYS USING NANOLIGOMERS
    Publication number: 20240150408
    Abstract: Compositions and methods involving nanoligomers are disclosed herein. Nanoligomers may include a targeting sequence and a nanostructure. A targeting sequence may include a polynucleotide binding domain and a transcription activation domain. A nanostructure may include a nanoparticle and a cell uptake domain.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 9, 2024
    Applicant: Sachi Bioworks Inc.
    Inventor: Prashant Nagpal
  • Antibody-evading virus vectors
    Patent number: 11976096
    Abstract: The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and vims capsids of the disclosure to a cell or to a subject in vivo.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: May 7, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry
  • ORGANOPHOSPHORUS NERVE AGENT HYDROLYZING ENZYMES
    Publication number: 20240141308
    Abstract: Aspects of the disclosure relate to phosphotriesterase (PTE) enzymes and PTE-related (PTER) enzymes and their use in hydrolyzing OPNAs.
    Type: Application
    Filed: April 15, 2022
    Publication date: May 2, 2024
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: David Borhani, Dylan Alexander Carlin, Alex Tucker
  • BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
    Publication number: 20240110206
    Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro. Specifically, the disclosure is directed to a prenyltransferase variant, a chimeric prenyltransferase comprising one or more portions of at least two different prenyltransferase proteins, and a fusion polypeptide comprising a CBG-type producing prenyltransferase and farnesyl pyrophosphate synthase.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 4, 2024
    Applicant: Ginkgo Bioworks, Inc.
    Inventors: Dylan Alexander Carlin, Brian Carvalho, Nicholas Flores, Katrina Forrest, Gabriel Rodriguez, Nathan W. Schmidt, Michelle Spencer
  • Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
    Patent number: 11905523
    Abstract: Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 20, 2024
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Daniel McCoy, Garrett E. Berry, David Dismuke